Alkermes, Inc.
Quick facts
Marketed products
- Aristada · Neuroscience · revenue 500
Aristada works by blocking dopamine receptors in the brain to help regulate abnormal thought and behavior patterns. - Baclofen ER · Neurology
Baclofen ER is a GABA-B receptor agonist that reduces neuronal excitability and muscle tone by enhancing inhibitory neurotransmission in the central nervous system. - LYBALVI · Psychiatry
LYBALVI is a combination of lurasidone (an atypical antipsychotic) and samidorphan (an opioid antagonist) that blocks dopamine and serotonin receptors while antagonizing opioid receptors to reduce antipsychotic-induced weight gain. - Motrin · Other
- Lybalvi · Neuroscience
Lybalvi blocks the action of opioids at their receptor sites in the brain. - VIVITROL 380mg
Phase 3 pipeline
- ALK3831 · Psychiatry/Neurology
ALK3831 is a long-acting injectable formulation of aripiprazole designed to provide sustained dopamine D2/D3 receptor antagonism for antipsychotic effect. - ALKS 2680 Dose 1 · Psychiatry/Neurology
ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms. - ALKS 3831
- ALKS 9072 · Pain Management
ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential. - ALKS 9072, High · Pain Management
ALKS 9072 is a mu opioid receptor agonist combined with an opioid antagonist designed to provide analgesia while reducing abuse potential. - ALKS 9072, Low · Psychiatry / Addiction Medicine
ALKS 9072 is a mu opioid receptor partial agonist designed to treat opioid use disorder by reducing cravings and withdrawal symptoms. - High Dose ALKS 5461 · Pain Management / Psychiatry
ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through antagonism at the opioid receptor. - Low Dose ALKS 5461 · Pain Management / Opioid Use Disorder
ALKS 5461 is a combination of buprenorphine and samidorphan that acts as a partial mu-opioid receptor agonist while blocking opioid-induced side effects through opioid antagonism. - NTX/BUP · Psychiatry / Addiction Medicine
NTX/BUP is a fixed-dose combination of naltrexone (an opioid antagonist) and buprenorphine (a partial opioid agonist) that reduces opioid cravings and withdrawal symptoms while blocking euphoric effects of additional opioid use. - NTX/PBO-B · Obesity / Metabolic Disease
NTX/PBO-B is a combination of naltrexone (an opioid antagonist) and bupropion (an antidepressant) designed to reduce appetite and promote weight loss. - OLZ/SAM · Psychiatry
OLZ/SAM is an oral, fixed-dose combination of olanzapine and samidorphan, a partial agonist at the μ-opioid receptor. - PBO-N/PBO-B · Pain
PBO-N/PBO-B is a partial opioid agonist.
Phase 2 pipeline
Phase 1 pipeline
- [14c]-Samidorphan oral
- [14c]-Samidorphan sublingual
- ALKS 33
- ALKS 33-BUP
- ALKS 9072, Med dose
- RDC-0313
- RDN-929 TBD dose
- Samidorphan IV
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: